COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE PRODUCT
AbbVie ABT-066 Biodrugs/ Drugs Autoimmune & Inflammation Psoriasis / Psoriatic arthritis / Crohn disease / Ulcerative colitis / Hidrosadenitis Supurativa 3PhIII ABT-066
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-368 Biodrugs/ Drugs Cancer Head cancer / Neck cancer 1PhI ABBV-368
Therapeutic area: Cancer
AbbVie ABT-199/GDC0199 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Chronic Lymphocytic Leukemia / Mieloma Multiple / Leucemia Mieloide Aguda 3PhIII ABT-199/GDC0199
Therapeutic area: Blood and Lymphatic systems / Cancer
AbbVie ABT-493 Biodrugs/ Drugs Infections C Hepatitis 3PhIII ABT-493
Therapeutic area: Infections
AbbVie ABT-333 Biodrugs/ Drugs Infections C Hepatitis 3PhIII ABT-333
Therapeutic area: Infections
AbbVie ABT-530 Biodrugs/ Drugs Infections C Hepatitis 3PhIII ABT-530
Therapeutic area: Infections
AbbVie ABT450/ABT-267 Biodrugs/ Drugs Infections C Hepatitis 3PhIII ABT450/ABT-267
Therapeutic area: Infections
AbbVie ABT-555 Biodrugs/ Drugs Central Nervous System Ischemic stroke / Spinal cord injury 2PhII ABT-555
Therapeutic area: Central Nervous System
AbbVie ABT-SLV187 Biodrugs/ Drugs Central Nervous System Parkinson 4Reg. ABT-SLV187
Therapeutic area: Central Nervous System
AbbVie Veliparib Biodrugs/ Drugs Cancer Breast Cancer / Ovarian cancer 3PhIII Veliparib
Therapeutic area: Cancer
AbbVie ABBV-399 Biodrugs/ Drugs Cancer NSCLC 2PhII ABBV-399
Therapeutic area: Cancer
AbbVie ABT-263 Biodrugs/ Drugs Blood and Lymphatic systems Myelofibrosis 3PhIII ABT-263
Therapeutic area: Blood and Lymphatic systems
AbbVie ABBV-951 Biodrugs/ Drugs Central Nervous System Parkinson 3PhIII ABBV-951
Therapeutic area: Central Nervous System
AbbVie ABBV-323 Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII ABBV-323
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-181 Biodrugs/ Drugs Cancer Solid tumors / Head cancer / Neck cancer 1PhI ABBV-181
Therapeutic area: Cancer
AbbVie ABBV-621 Biodrugs/ Drugs Cancer Colorrectal cancer / Acute Myeloid Leukemia 1PhI ABBV-621
Therapeutic area: Cancer
AbbVie ABT-494 Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthritis / Chron Disease / Ulcerative Colitis/ Atopic Dermatitis / Psoriasic Arthritis / Axial Spondiloarthritis / Giant Cell Artheritis / Juvenil Idiopatic Arthritis / Lupus / Ankylosing Spondylitis 3PhIII ABT-494
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-8E12 Biodrugs/ Drugs Central Nervous System Alzheimer 2PhII ABBV-8E12
Therapeutic area: Central Nervous System
AbbVie Humira (adalimumab) Biodrugs/ Drugs Autoimmune & Inflammation Hidradenitis Suppurativa / Uveitis / Ulcerative colitis/ Chron Disease / Rheumatoid Arthritis / Psoriasis / Psoriatic Arthritis 4Reg. Humira (adalimumab)
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid tumors 1PhI ABBV-927
Therapeutic area: Cancer
AbbVie ABBV-647 Biodrugs/ Drugs Cancer Lung cancer 1PhI ABBV-647
Therapeutic area: Cancer
Amgen Evolocumab Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Hypercholesterolemia, mixed dyslipidemia and Homozygous familial hypercholesterolemia 4Reg. Evolocumab
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Amgen Romiplostim Biodrugs/ Drugs Blood and Lymphatic systems Adult chronic - immune (idiopatic)-thrombocytopenic-purpura (ITP) 4Reg. Romiplostim
Therapeutic area: Blood and Lymphatic systems
Amgen Talimogene laherparepvec Biodrugs/ Drugs Cancer Malignant melanoma 4Reg. Talimogene laherparepvec
Therapeutic area: Cancer
Amgen Cinacalcet Biodrugs/ Drugs Autoimmune & Inflammation
Kidney and Genitourinary system
Secondary hyperparathyroidism / Reducation of hypercalcaemia in patinents with parathyroid carcinoma or primary HPT 4Reg. Cinacalcet
Therapeutic area: Autoimmune & Inflammation / Kidney and Genitourinary system
Amgen Etelcalcetide Biodrugs/ Drugs Metabolic / Endocrinology Secondary Hyperparathyroidism 4Reg. Etelcalcetide
Therapeutic area: Metabolic / Endocrinology
Amgen Romosozumab Biodrugs/ Drugs Musculoskeletal Disorders
Women´s health
Postmenopausal osteoporosis 3PhIII Romosozumab
Therapeutic area: Musculoskeletal Disorders / Women´s health
Amgen Denosumab Biodrugs/ Drugs Musculoskeletal Disorders Osteoporosis in postmenopausal women / Treatment of bone loss associated with hormone ablation in men with prostate cancer 4Reg. Denosumab
Therapeutic area: Musculoskeletal Disorders
Amgen Blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute lymphoblastic leukaemia 4Reg. Blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Denosumab Biodrugs/ Drugs Cancer Giant cell tumour of the bone 2PhII Denosumab
Therapeutic area: Cancer
Amgen Omecantiv mecarbil Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure 3PhIII Omecantiv mecarbil
Therapeutic area: Cardiovascular and circulatory systems
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Breast: Metastatic Non-small cell lung: Advanced Myelodysplastic Syndromes (MDS): post hypomethylating agent (HMA) failure 2PhII CC 486
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CD19 CAR-T (JCAR017) Biodrugs/ Drugs Blood and Lymphatic systems Aggressive large B-cell lymphoma: Relapsed/refractory 1PhI CD19 CAR-T (JCAR017)
Therapeutic area: Blood and Lymphatic systems
Celgene VIDAZA® (azacitidine for injection) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Acute myeloid laeukemia (AML) (>30% blasts) 4Reg. VIDAZA® (azacitidine for injection)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-93269 Biodrugs/ Drugs Blood and Lymphatic systems Multiple Myeloma (MM) Relapsed/ refractory 1PhI CC-93269
Therapeutic area: Blood and Lymphatic systems
Celgene CC 486 Biodrugs/ Drugs Blood and Lymphatic systems Lymphoma 1PhI CC 486
Therapeutic area: Blood and Lymphatic systems
Celgene Morgensen (GED-0301) Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Ulcerative colitis 2PhII Morgensen (GED-0301)
Therapeutic area: Autoimmune & Inflammation / Digestive System
Celgene PD-L1 Inhibitor: durvalumab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS) Acute Myeloid Leukemia (AML) 2PhII PD-L1 Inhibitor: durvalumab
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene REVLIMID® (lenalidomide) Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse large B-cell lymphoma (ABC subtype): First line Indolent lymphoma: relapsed/refractory Follicular lymphoma: first line 3PhIII REVLIMID® (lenalidomide)
Therapeutic area: Blood and Lymphatic systems / Cancer
Celgene CC-486 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Myelodysplastic Syndromes (MDS): lower-risk Post-induction AML maintenance 3PhIII CC-486
Therapeutic area: Blood and Lymphatic systems / Cancer
Gilead Sciences Simtuzumab Biodrugs/ Drugs Respiratory and Pulmonary system Idiopathic pulmonary fibrosis 2PhII Simtuzumab
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology Primary Sclerosing Cholangit 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Emtricitabine/Tenofovir alafenamide FDC
Therapeutic area: Infections
Gilead Sciences GS-4875 (TPL2 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Inflammatory Bowel 1PhI GS-4875 (TPL2 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences KITE-718 ( MAGE A3/A6) Biodrugs/ Drugs Cancer Solid tumor. 1PhI KITE-718 ( MAGE A3/A6)
Therapeutic area: Cancer
Gilead Sciences GS-0976 ( ACC Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology NASH 2PhII GS-0976 ( ACC Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Elvitegravir/Cobicistat /Emtricitabine/Tenofovir alafenamide STR
Therapeutic area: Infections
Gilead Sciences Remdesivir ( Gs-5734, Nuc. Inhibitor) Biodrugs/ Drugs Infections Ebola Virus infection 2PhII Remdesivir ( Gs-5734, Nuc. Inhibitor)
Therapeutic area: Infections
Gilead Sciences Andecaliximab (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Gastric cancer 3PhIII Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences Filgotinib (JAK1 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid Arthritis 3PhIII Filgotinib (JAK1 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Vestalimod ( GS-9620, TRL-7 agonist) Biodrugs/ Drugs Infections HIV/AIDS 1PhI Vestalimod ( GS-9620, TRL-7 agonist)
Therapeutic area: Infections
Gilead Sciences GS-5806 (fusion inhibitor) Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Respiratory syncytial virus 2PhII GS-5806 (fusion inhibitor)
Therapeutic area: Infections / Respiratory and Pulmonary system
Gilead Sciences Andecaliximab (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 1PhI Andecaliximab (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences Filgotinib (JAK1 inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Crohn's Disease and Ulcerative colitis 2PhII Filgotinib (JAK1 inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences GS-62'7 (capsid inhibitor) Biodrugs/ Drugs Infections HIV/AIDS 1PhI GS-62'7 (capsid inhibitor)
Therapeutic area: Infections
Gilead Sciences GS-6615 (late sodium current inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Ventricular tachycardia / Ventricular fibrillation 2PhII GS-6615 (late sodium current inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences Entosplenitib (Syk inhibitor) Biodrugs/ Drugs Blood and Lymphatic systems Hematological malignances 2PhII Entosplenitib (Syk inhibitor)
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Presatovir ( Fusion inhibitor) Biodrugs/ Drugs Respiratory and Pulmonary system Respiratory Syncytial Virus 2PhII Presatovir ( Fusion inhibitor)
Therapeutic area: Respiratory and Pulmonary system
Gilead Sciences GS-9131 (NRTI) Biodrugs/ Drugs Infections HIV/AIDS 3PhIII GS-9131 (NRTI)
Therapeutic area: Infections
Gilead Sciences GS-9722 (bNab) Biodrugs/ Drugs Infections HIV/AIDS 1PhI GS-9722 (bNab)
Therapeutic area: Infections
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Cardiovascular and circulatory systems Pulmonary arterial hypertension 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Cardiovascular and circulatory systems
Gilead Sciences GS-9876 ( Syk Inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Sjogren's Syndrome 2PhII GS-9876 ( Syk Inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir Biodrugs/ Drugs Infections HIV/AIDS - PreExposure Profilaxis 3PhIII Emtricitabine/Tenofovir alafenamide FDC/ Bictegravir/ Emtricitabine/Tenofovir
Therapeutic area: Infections
Gilead Sciences ERK Inhibitor Biodrugs/ Drugs Cancer Cancer 1PhI ERK Inhibitor
Therapeutic area: Cancer
Gilead Sciences Axicabtagene ciloleucel Biodrugs/ Drugs Blood and Lymphatic systems DLBCL ,PMBCL & TFL 3PhIII Axicabtagene ciloleucel
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-9688 (TLR-8 Agonist) Biodrugs/ Drugs Infections HBV 1PhI GS-9688 (TLR-8 Agonist)
Therapeutic area: Infections
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences GS-9876 (Syk inhibitor) Biodrugs/ Drugs Autoimmune & Inflammation Lupus 2PhII GS-9876 (Syk inhibitor)
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Alafenamide STR Biodrugs/ Drugs Infections HIV/AIDS 3PhIII Alafenamide STR
Therapeutic area: Infections
Gilead Sciences Axicabtagene colileucel Biodrugs/ Drugs Blood and Lymphatic systems Indolent NHL 2PhII Axicabtagene colileucel
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Selonsertib ( ASK-1 Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology NASH 3PhIII Selonsertib ( ASK-1 Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences GS-5745 (MMP9 mAb inhibitor) Biodrugs/ Drugs Cancer Solid tumors 2PhII GS-5745 (MMP9 mAb inhibitor)
Therapeutic area: Cancer
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems MCL 2PhII KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Tirabrutinib (BTK inhibitor) Biodrugs/ Drugs Blood and Lymphatic systems B-cell malignancies 2PhII Tirabrutinib (BTK inhibitor)
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Selonsertib ( ASK-1 Inhibitor) Biodrugs/ Drugs Metabolic / Endocrinology Alcoholic Hepatitis 2PhII Selonsertib ( ASK-1 Inhibitor)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences Momelotinib Biodrugs/ Drugs Cancer Pancreatic cancer 2PhII Momelotinib
Therapeutic area: Cancer
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems Adult ALL 1PhI KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology NASH 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences GS-4997 (ASK-1 inhibitor) Biodrugs/ Drugs Digestive System Nonalcoholic steatohaepatitis 2PhII GS-4997 (ASK-1 inhibitor)
Therapeutic area: Digestive System
Gilead Sciences KTE-C19 Biodrugs/ Drugs Blood and Lymphatic systems Pedriatic ALL 1PhI KTE-C19
Therapeutic area: Blood and Lymphatic systems
Gilead Sciences Simtuzumab Biodrugs/ Drugs Digestive System Liver fibrosis, primary sclerosing cholangitis, nonalcoholic steatohaepatitis 2PhII Simtuzumab
Therapeutic area: Digestive System
Gilead Sciences GS-9674 (FXR Agonist) Biodrugs/ Drugs Metabolic / Endocrinology Primary Bilinary Cirrhosis 2PhII GS-9674 (FXR Agonist)
Therapeutic area: Metabolic / Endocrinology
Gilead Sciences KITE-585 ( anti-BCMA) Biodrugs/ Drugs Blood and Lymphatic systems MM 1PhI KITE-585 ( anti-BCMA)
Therapeutic area: Blood and Lymphatic systems
Incyte Biosciences Iberia INCAGN1876 Biodrugs/ Drugs Cancer Solid tumors (Discovery alliance with Agenus) 2PhII INCAGN1876
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Cholangiocarcinoma 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer 8p11 MPN 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Follicular lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Marginal zone lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Mantle cell lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer MSI-H endometrial cancer (In collaboration with MacroGenics) 1PhI INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Merkel cell carcinoma (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Anal cancer (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Chronic graft-versus-host disease 3PhIII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) 2PhII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCB01158 Biodrugs/ Drugs Cancer Solid tumors (Co-development with Calithera) 2PhII INCB01158
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Bladder cancer 2PhII Pemigatinib
Therapeutic area: Cancer
Merck KGaA Avelumab Biodrugs/ Drugs Cancer anti-PD-L1 mAb. Non-small cell lung cancer 1L 3PhIII Avelumab
Therapeutic area: Cancer
Merck KGaA Abituzumab Biodrugs/ Drugs Cancer pan-αν integrin inhibiting mAb. Colorectal Cancer 1L 2PhII Abituzumab
Therapeutic area: Cancer
Merck KGaA M4344 Biodrugs/ Drugs Cancer ATR inhibitor. Solid tumors 1PhI M4344
Therapeutic area: Cancer
Merck KGaA Avelumab Biodrugs/ Drugs Cancer anti-PD-L1 mAb. Urothelial cancer 1L-M 4Reg. Avelumab
Therapeutic area: Cancer
Merck KGaA M8891 Biodrugs/ Drugs Cancer MetAP2 inhibitor. Solid tumors 1PhI M8891
Therapeutic area: Cancer
Merck KGaA Atacicept Biodrugs/ Drugs Autoimmune & Inflammation Anti-BlyS/APRIL fusion protein. Systemic lupus erythematosus / IgA nephropathy 2PhII Atacicept
Therapeutic area: Autoimmune & Inflammation
Merck KGaA M5049 Biodrugs/ Drugs Autoimmune & Inflammation TLR7/8 antagonist. Immunology 1PhI M5049
Therapeutic area: Autoimmune & Inflammation
Merck KGaA Avelumab Biodrugs/ Drugs Cancer anti-PD-L1 mAb. Several types of cancer (Merkel cell cancer 1L / urothelial cancer / solid tumors and non-small cell lung cancer 1L in combination with talazoparib, axitinib, ALK inhibitors, cetuximab, or chemotherapy). 2PhII Avelumab
Therapeutic area: Cancer
Merck KGaA Tepotinib Biodrugs/ Drugs Cancer MET kinase inhibitor. Non-small cell lung cancer 2PhII Tepotinib
Therapeutic area: Cancer
Merck KGaA M6495 Biodrugs/ Drugs Autoimmune & Inflammation anti-ADAMTS-5 nanobody. Osteoarthritis 1PhI M6495
Therapeutic area: Autoimmune & Inflammation
Merck KGaA Bintrafusp alfa Biodrugs/ Drugs Cancer TGFbeta trap/anti-PD-L1. Solid tumors 1PhI Bintrafusp alfa
Therapeutic area: Cancer
Merck KGaA Sprifermin Biodrugs/ Drugs Autoimmune & Inflammation fibroblast growth factor 18. Osteoarthritis 2PhII Sprifermin
Therapeutic area: Autoimmune & Inflammation
Merck KGaA M3258 Biodrugs/ Drugs Cancer LMP7 inhibitor. Multiple myeloma 1PhI M3258
Therapeutic area: Cancer
Merck KGaA M9241 (NHS-IL12) Biodrugs/ Drugs Cancer Cancer immunotherapy. Solid tumors in combination with avelumab 1PhI M9241 (NHS-IL12)
Therapeutic area: Cancer
Merck KGaA Peposertib (M3814) Biodrugs/ Drugs Cancer DNA-PK inhibitor. Rectal cancer 2PhII Peposertib (M3814)
Therapeutic area: Cancer
Merck KGaA M1095 (ALX-0761) Biodrugs/ Drugs Autoimmune & Inflammation anti-IL-17 A/F nanobody. Psoriasis 2PhII M1095 (ALX-0761)
Therapeutic area: Autoimmune & Inflammation
Merck KGaA Peposertib (M3814) Biodrugs/ Drugs Cancer DNA-PK inhibitor. Solid tumors in combination with avelumab 1PhI Peposertib (M3814)
Therapeutic area: Cancer
Merck KGaA Bintrafusp alfa Biodrugs/ Drugs Cancer TGFbeta trap/anti-PD-L1. Non-small cell lung cancer 1L / 1L/2L / Locally advanced non-small cell lung cancer / Biliary tract cancer 1L / Biliary tract cancer 2L / Cervical cancer 2L 2PhII Bintrafusp alfa
Therapeutic area: Cancer
Merck KGaA M1774 Biodrugs/ Drugs Cancer ATR inhibitor. Solid tumors 1PhI M1774
Therapeutic area: Cancer
Merck KGaA M5717 Biodrugs/ Drugs Infections PeEF2 inhibitor. Malaria 1PhI M5717
Therapeutic area: Infections
Merck KGaA Berzosertib (M6620) Biodrugs/ Drugs Cancer ATR inhibitor. Solid tumors 1PhI Berzosertib (M6620)
Therapeutic area: Cancer
Merck KGaA Tepotinib Biodrugs/ Drugs Cancer MET kinase inhibitor. Non-small cell lung cancer, METex14 skipping 4Reg. Tepotinib
Therapeutic area: Cancer
Merck KGaA Evobrutinib Biodrugs/ Drugs Central Nervous System BTK inhibitor. Multiple sclerosis 3PhIII Evobrutinib
Therapeutic area: Central Nervous System
MSD Pembrolizumab Biodrugs/ Drugs Cancer Neoadjuvant treatment Platinum Doublet Chemotherapy +/-Pembrolizumab followed by Surgery 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD MK3475/Enfortumab Biodrugs/ Drugs Cancer Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer. 3PhIII MK3475/Enfortumab
Therapeutic area: Cancer
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer V937 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 Biodrugs/ Drugs Cancer Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selected Solid Tumors. 2PhII Pembrolizumab/MK-7684
Therapeutic area: Cancer
MSD Olaparib/Pembrolizumab Biodrugs/ Drugs Cancer Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated 2PhII Olaparib/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer first Line Study of Pembrolizumab +/- Ipilimumab in NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD MK6482 Biodrugs/ Drugs Cancer MK-6482 Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET). 2PhII MK6482
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. 3PhIII Posaconazole
Therapeutic area: Infections
MSD Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum Biodrugs/ Drugs Cancer Platform trial: Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or CarboplatinThe first-line treatment of participants with extensive-stage small cell lung cancer. 2PhII Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum
Therapeutic area: Cancer
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer V937 as Monotherapy or in Combination with Pembrolizumab in Participants With BCG-Unresponsive High-Risk NMIBC 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Vaccines Infections VPH in preadolescents and adolescents 3PhIII Gardasil 9
Therapeutic area: Infections
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Gardasil 9 Vaccines Infections 9vHPV vaccine in adult males 20 to 45 years of age 3PhIII Gardasil 9
Therapeutic area: Infections
MSD Islatravir Biodrugs/ Drugs Infections HIV Infection 3PhIII Islatravir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD MK1308A (quavonlimab+pembro) Biodrugs/ Drugs Cancer A phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK- 3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colo 2PhII MK1308A (quavonlimab+pembro)
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Triple-Negative Breast Cancer (mTNBC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Molnupiravir Biodrugs/ Drugs Infections Molnupiravir in non-hospitalized patients with COVID-19. 3PhIII Molnupiravir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Versus Placebo in Surgically Resected or Ablated HCC Patients 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/ Lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab + lenvatinib por previously untreated advanced or metastatic nccRCC. 2PhII Pembrolizumab/ Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 or MK-4830 or MK-5890 Biodrugs/ Drugs Cancer Umbrella trial in First Line Metastatic non-squamous and squamous Non-small Cell Lung Cancer Subjects with pembrolizumab and MK-7684 or MK-4830 and in previously treated PD-1/PDL-1 patients receiving pembrolizumab and MK-5890 or MK-4830 2PhII Pembrolizumab/MK-7684 or MK-4830 or MK-5890
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Phase III Pembro + Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Study of Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab / Olaparib Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib , Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung 3PhIII Pembrolizumab / Olaparib
Therapeutic area: Cancer
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer Study of ITu V937 in Combination with Pembrolizumab selected solid tumors 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD V160 Vaccines Infections Prevention CMVin women 16-35 dosis vx 3 dosis 2PhII V160
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer Study of ITu V937 in Combination with Pembrolizumab selected solid tumors. 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Trastuzumab + Chemotherapy with/without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors. 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase II (biomarker directed) Pembrolizumab Based Combination Therapy for Advanced Non-Small Cell Lung Cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD MK4280A (favezelimab+pembro) Biodrugs/ Drugs Cancer A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer. 3PhIII MK4280A (favezelimab+pembro)
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line study of pembrolizumab +/- epacadostat in NSCLC 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib Biodrugs/ Drugs Cancer Umbrella trial of Immune and Targeted Combination Therapies as First Line treatment in Renal Clear Cell Carcinoma subjects with MK1308A + Lenvatinib or MK 4280A + Lenvatinib or MK 6482 + Pembrolizumab + Lenvatinib vs Pembrolizumab + Lenvatinib or as Secon 2PhII MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line etoposide/platinum with or without pembrolizumab in extensive stage small cell lung cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) 2PhII Prevymis (Letermovir)
Therapeutic area: Infections
MSD MK6482 + lenvatinib / cabozantinib Biodrugs/ Drugs Cancer MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. 3PhIII MK6482 + lenvatinib / cabozantinib
Therapeutic area: Cancer
MSD MK4830 Biodrugs/ Drugs Cancer MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors 1PhI MK4830
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 10 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Anacetrapib Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease 3PhIII Anacetrapib
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Adjuvant chemotherapy plus pembrolizumab/placebo for endometrial cancer after surgery with curative intent. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Lenvatinib/Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma 3PhIII Lenvatinib/Pembrolizumab
Therapeutic area: Cancer
MSD Pneumococcal vaccine polyvalent Vaccines Infections Paedriatric Prevention of pneumococal infection with V114 3PhIII Pneumococcal vaccine polyvalent
Therapeutic area: Infections
MSD Olaparib Biodrugs/ Drugs Cancer Olaparib in Participants with solid tumors Previously Treated 2PhII Olaparib
Therapeutic area: Cancer
MSD Lenvatinib/Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma. 3PhIII Lenvatinib/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD RSV Vaccine Biodrugs/ Drugs Infections VRS prevention in preterm infants 2PhII RSV Vaccine
Therapeutic area: Infections
MSD MK4830 Biodrugs/ Drugs Cancer MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors. 1PhI MK4830
Therapeutic area: Cancer
MSD Gefapixant Biodrugs/ Drugs Women´s health Moderate to Severe Endometriosis-related Pain 2PhII Gefapixant
Therapeutic area: Women´s health
MSD Mavezelimab/Pembrolizumab Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI Mavezelimab/Pembrolizumab
Therapeutic area: Cancer
MSD MK6482 Biodrugs/ Drugs Cancer MK-0482 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors. 1PhI MK6482
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pemetrexed+Platinum with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with recurrent ovarian cancer 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Vericiguat Biodrugs/ Drugs Cardiovascular and circulatory systems Heart failure with reduced ejection Fraction 3PhIII Vericiguat
Therapeutic area: Cardiovascular and circulatory systems
MSD Pembrolizumab Biodrugs/ Drugs Cancer 20 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD ZINPLAVA Biodrugs/ Drugs Infections In Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) 3PhIII ZINPLAVA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab (in Combination with MK-6482 and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment for ccRCC. 3PhIII pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Respiratory and Pulmonary system Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients 1PhI ZERBAXA
Therapeutic area: Respiratory and Pulmonary system
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with Daratumumab in subjects Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pomalidomide and low dose dexamethasone with pembrolizumab in refractory or relapsed Multiple Myeloma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD MK-1308A/Lenvatinib Biodrugs/ Drugs Cancer MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma. 2PhII MK-1308A/Lenvatinib
Therapeutic area: Cancer
MSD MK1454/Pembrolizumab Biodrugs/ Drugs Cancer Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma 2PhII MK1454/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Lenvatinib/Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor. 2PhII Lenvatinib/Pembrolizumab
Therapeutic area: Cancer
MSD MK-5890/Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors. 1PhI MK-5890/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated. 2PhII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subcutaneous Injection Versus Intravenous Infusion in Participants with Advanced Melanoma. 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer PD-L1 Strong Metastatic Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/TACE Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma 3PhIII Pembrolizumab/TACE
Therapeutic area: Cancer
MSD MK1454/Pembrolizumab Biodrugs/ Drugs Cancer Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma. 2PhII MK1454/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced/Unresectable or Metastatic Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD HIF-2α inhibitor Biodrugs/ Drugs Cancer MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies 3PhIII HIF-2α inhibitor
Therapeutic area: Cancer
MSD MK-3655 Biodrugs/ Drugs Metabolic / Endocrinology MK-3655 in Individuals with Pre-Cirrhotic Nonalcoholic Steatohepatitis. 2PhII MK-3655
Therapeutic area: Metabolic / Endocrinology
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-genera 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Lenvatinib Biodrugs/ Drugs Cancer Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies. 2PhII Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 or MK-4830 or MK-5890 Biodrugs/ Drugs Cancer Umbrella trial in First Line Metastatic non-squamous and squamous Non-small Cell Lung Cancer Subjects with pembrolizumab and MK-7684 or MK-4830 and in previously treated PD-1/PDL-1 patients receiving pembrolizumab and MK-5890 or MK-4830. 2PhII Pembrolizumab/MK-7684 or MK-4830 or MK-5890
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Inactivated VZV Vaccine Vaccines Blood and Lymphatic systems
Cancer
Adult Patients with Solid Tumor or Hematologic Malignancy 3PhIII Inactivated VZV Vaccine
Therapeutic area: Blood and Lymphatic systems / Cancer
MSD Pembrolizumab/ Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib in Combination with Pembrolizumab in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment. 3PhIII Pembrolizumab/ Lenvatinib
Therapeutic area: Cancer
MSD BET Inhibitor Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI BET Inhibitor
Therapeutic area: Cancer
MSD Anti CTLA-4/Pembrolizumab Biodrugs/ Drugs Cancer MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase) 2PhII Anti CTLA-4/Pembrolizumab
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Infections Pediatric subjects with nosocomial pneumonia (HABP/VABP) 1PhI ZERBAXA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer 1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD RECARBRIO (mk7655A) Biodrugs/ Drugs Infections Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection 3PhIII RECARBRIO (mk7655A)
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab administrated with Platinum doublet chemotherapy in Metastasic Squamous or Nonsquamous non small cell lung cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab + lenvatinib versus docetaxel for metastatic Non-Small Cell Lung Cancer after platinum doublet chemotherapy and immunotherapy 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-genera 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Efinopegdutide (MK-6024) Biodrugs/ Drugs Metabolic / Endocrinology Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease. 2PhII Efinopegdutide (MK-6024)
Therapeutic area: Metabolic / Endocrinology
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Study of Pembrolizumab/Epacadostat/Chemotherapy in Metastatic Non-small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase III extension study for participants with advanced tumors in pembrolizumab trials 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Sugammadex/BRIDION Biodrugs/ Drugs Others Anesthesiology. Reversal of Neuromuscular Blockade in Pediatric Population 4Reg. Sugammadex/BRIDION
Therapeutic area: Others
MSD Pembrolizumab/ Lenvatinib Biodrugs/ Drugs Cancer .Lenvatinib plus Pembrolizumab plus chemotherapy for the treatment of Advanced/Metastatic gastroesophageal adenocarcinoma. 3PhIII Pembrolizumab/ Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD RIG-I Biodrugs/ Drugs Cancer Advanced/Metastatic or Recurrent Solid Tumors 1PhI RIG-I
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 Biodrugs/ Drugs Cancer Pembrolizumab in combination with anti-TIGIT or Pembrolizumab in combination with anti-TIGIT plus Docetaxel in metastasic non small lung cancer with progressive disease after treatment with a platinum doublet chemotherapy or immunotheraphy. 2PhII Pembrolizumab/MK-7684
Therapeutic area: Cancer
MSD MK-5890/Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors 1PhI MK-5890/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) 4Reg. Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Gefapixant Biodrugs/ Drugs Respiratory and Pulmonary system Chronic cough 3PhIII Gefapixant
Therapeutic area: Respiratory and Pulmonary system
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Compared with Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III No 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Doravirine Biodrugs/ Drugs Infections HIV Infection 3PhIII Doravirine
Therapeutic area: Infections
MSD Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280 Biodrugs/ Drugs Cancer Platform trial: Pembrolizumab in Combination with Investigational Agents in PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy. 2PhII Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280
Therapeutic area: Cancer
MSD Lenvatinib Biodrugs/ Drugs Cancer Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies 2PhII Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lung cancer 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia 1PhI Posaconazole
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Lenvatinib 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Olaparib Biodrugs/ Drugs Cancer Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer. 2PhII Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) and Relapsed or Refractory Richter Syndrome 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of CMV disease in D+/R- kidney transplant recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Golimumab Biodrugs/ Drugs Autoimmune & Inflammation Non-radiographic axial Spondyloarthritis 4Reg. Golimumab
Therapeutic area: Autoimmune & Inflammation
MSD Favezelimab/Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumor. 1PhI Favezelimab/Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Olaparib Biodrugs/ Drugs Cancer Olaparib vs Olaparib + Bevacizumab vs 5FU + Bevacizumab in metastasic colorectal cancer 3PhIII Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lubng cancer 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC). 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Urothelial Cancer. Pembro +/- Epacadostat 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer. 2PhII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer High-risk Non Muscle Invassive Bladder Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Perioperative Pembrolizumab for Cis-Ineligible MIBC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Infections Pediatric Subjects with Complicated Intra-Abdominal Infection 2PhII ZERBAXA
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible MIBC. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD 15-valent Pneumococcal Conjugate Vaccine Vaccines Infections Pneumoccoco in healthy adults 50 years of age or older 3PhIII 15-valent Pneumococcal Conjugate Vaccine
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab vs chemotherapy in patients with advanced melanoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD V-937/Pembrolizumab Biodrugs/ Drugs Cancer Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors. 2PhII V-937/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer High-risk Non Muscle Invassive Bladder Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Lenvatinib/Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor 2PhII Lenvatinib/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib/Belzutifan Biodrugs/ Drugs Cancer Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors. 2PhII Pembrolizumab/Lenvatinib/Belzutifan
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in children and young adults with newly diagnosed Classical Hodgkin Lymphoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Progressive or recurrent Intermediate or High risk, Non-muscle invasive Urothelial Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Perioperative Pembrolizumab for Cis-Ineligible MIBC. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
Novo Nordisk Pharma AM833 (amilyn analogue) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI AM833 (amilyn analogue)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma G530L (glucagon analogue/liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI G530L (glucagon analogue/liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma PYY1562 (analogue peptid YY) Biodrugs/ Drugs Metabolic / Endocrinology Obesity 1PhI PYY1562 (analogue peptid YY)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 in paediatric population 3PhIII Liraglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Nonacog beta pegol Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia B 4Reg. Nonacog beta pegol
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Monoclonal antibody anti Il-21 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 2PhII Monoclonal antibody anti Il-21
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma N8-GP (glycopegylated recombinant FVIII) Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII N8-GP (glycopegylated recombinant FVIII)
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Oral semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Oral semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Faster-acting insulin aspart (FIAsp) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and type 2 4Reg. Faster-acting insulin aspart (FIAsp)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Insulin LA287 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Insulin LA287
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Somapacitan(Long-acting growth hormone) Biodrugs/ Drugs Metabolic / Endocrinology Growth hormone deficiency 3PhIII Somapacitan(Long-acting growth hormone)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegAsp (combination insulin degludec + insulin aspart) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 and type 1 4Reg. IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide NASH Biodrugs/ Drugs Metabolic / Endocrinology Non-alcoholic steatohepatitis 2PhII Semaglutide NASH
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Concizumab Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A and B 2PhII Concizumab
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma IDegLira (combination insulin degludec + liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 4Reg. IDegLira (combination insulin degludec + liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Prandial Bioedge Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and 2 1PhI Prandial Bioedge
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide 3mg Biodrugs/ Drugs Metabolic / Endocrinology Obesity 4Reg. Liraglutide 3mg
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Semaglutide obesidad Biodrugs/ Drugs Metabolic / Endocrinology Obesity 3PhIII Semaglutide obesidad
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Turoctocog alfa Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 4Reg. Turoctocog alfa
Therapeutic area: Blood and Lymphatic systems
Roche BRAF KIN INH (2) Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI BRAF KIN INH (2)
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII ALEGLITAZAR
Therapeutic area: Metabolic / Endocrinology
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of brain 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems Acute myocardial infarction 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation ulcerative colitis 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation
Roche IPATASERTIB Biodrugs/ Drugs Cancer Breast cancer 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII Tecentriq
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer plasma cell neoplasm 3PhIII Tecentriq
Therapeutic area: Cancer
Roche herceptin Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 4Reg. herceptin
Therapeutic area: Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII VANUCIZUMAB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche BASIMGLURANT Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes Fragile X Syndrome 2PhII BASIMGLURANT
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Malignant neoplasms of lymphoid haematopoietic + 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lungs 4Reg. TARCEVA
Therapeutic area: Cancer
Roche BET Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 1PhI BET
Therapeutic area: Blood and Lymphatic systems
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche PATECLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII PATECLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII PERJETA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site. 4Reg. AVASTIN
Therapeutic area: Cancer
Roche CD40 IMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CD40 IMAB
Therapeutic area: Cancer
Roche CEA IL2V Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA IL2V
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant melanoma of skin 3PhIII COBIMETINIB
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche FAP 4-1BBL iMAb Biodrugs/ Drugs Cancer Solid tumor 1PhI FAP 4-1BBL iMAb
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Prostate cancer 3PhIII IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 4Reg. Tecentriq
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Prostate cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche IL22 Fc Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 1PhI IL22 Fc
Therapeutic area: Autoimmune & Inflammation
Roche ALPHA7 NIC AGO Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ALPHA7 NIC AGO
Therapeutic area: Central Nervous System
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Other + unspecif. types of non-Hodgkin's lymphoma 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CMV ANTI Biodrugs/ Drugs Infections Cytomegaloviral disease 2PhII CMV ANTI
Therapeutic area: Infections
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII KADCYLA
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Breast Cancer 3PhIII TASELISIB
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Breast cancer 2PhII COTELLIC
Therapeutic area: Cancer
Roche OX40 Biodrugs/ Drugs Cancer Breast cancer 4Reg. OX40
Therapeutic area: Cancer
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 2PhII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII TASELISIB
Therapeutic area: Cancer
Roche cadherin-11 MAb Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthritis 2PhII cadherin-11 MAb
Therapeutic area: Autoimmune & Inflammation
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII Tecentriq
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Irritable bowel syndrome 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche PARSATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII PARSATUZUMAB
Therapeutic area: Cancer
Roche HCV POL INH PRO Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII HCV POL INH PRO
Therapeutic area: Infections
Roche FAP IL2V FP Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI FAP IL2V FP
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer triple negative breast cancer 3PhIII IPATASERTIB
Therapeutic area: Cancer
Roche Venclexta Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's Lymphoma 2PhII Venclexta
Therapeutic area: Blood and Lymphatic systems
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IPATASERTIB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Renal cell carcinoma 3PhIII Tecentriq
Therapeutic area: Cancer
Roche IL22 Fc Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 2PhII IL22 Fc
Therapeutic area: Autoimmune & Inflammation
Roche ANTI-INFLUENZA A Biodrugs/ Drugs Infections Influenza 2PhII ANTI-INFLUENZA A
Therapeutic area: Infections
Roche PEGASYS Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII PEGASYS
Therapeutic area: Infections
Roche CRENEZUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII CRENEZUMAB
Therapeutic area: Central Nervous System
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII KADCYLA
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Colorectal cancer 3PhIII COTELLIC
Therapeutic area: Cancer
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 3PhIII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII TARCEVA
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Diffuse non-hodgkin's lymphoma 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche CIF MEK INH Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CIF MEK INH
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII Tecentriq
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche GANTENERUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII GANTENERUMAB
Therapeutic area: Central Nervous System
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII PDL1 MAB
Therapeutic area: Cancer
Roche LAMPALIZUMAB Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 4Reg. LAMPALIZUMAB
Therapeutic area: Ophthalmology and optometry
Roche FAP IL2V FP Biodrugs/ Drugs Cancer non-Small cell lung cancer 2PhII FAP IL2V FP
Therapeutic area: Cancer
Roche MIRCERA Biodrugs/ Drugs Blood and Lymphatic systems Chronic renal failure anemia 2PhII MIRCERA
Therapeutic area: Blood and Lymphatic systems
Roche DANOPREVIR Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII DANOPREVIR
Therapeutic area: Infections
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche Venclexta Biodrugs/ Drugs Blood and Lymphatic systems Lymphoid leukaemia 3PhIII Venclexta
Therapeutic area: Blood and Lymphatic systems
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Giant Cel arteritis 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer triple negative breast cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Breast cancer 3PhIII KADCYLA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of cervix uteri 2PhII AVASTIN
Therapeutic area: Cancer
Roche TAMIFLU Biodrugs/ Drugs Infections Influenza 1PhI TAMIFLU
Therapeutic area: Infections
Roche COTELLIC Biodrugs/ Drugs Cancer Malignant melanoma of skin 4Reg. COTELLIC
Therapeutic area: Cancer
Roche selicrelumab Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI selicrelumab
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of pancreas 2PhII TARCEVA
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche XOLAIR Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Dermatitis (Allergic Contact) 3PhIII XOLAIR
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Malignant neoplams of lymphoid haematopoietic 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche EM MS BIOMARKER Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM MS BIOMARKER
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche mPI3K alpha inh Biodrugs/ Drugs Cancer Breast cancer 1PhI mPI3K alpha inh
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Non-small cell lung cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Other malignant neoplasms of skin 1PhI DULIGOTUZUMAB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII PICTILISIB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Cardiovascular and circulatory systems Other necrotizing vasculopathies 3PhIII MABTHERA
Therapeutic area: Cardiovascular and circulatory systems
Roche GAZYVA Biodrugs/ Drugs Autoimmune & Inflammation systemic lupus erythematosus 2PhII GAZYVA
Therapeutic area: Autoimmune & Inflammation
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Systemic lupus erythematosus 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant melanoma of skin 4Reg. ZELBORAF
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Rheumatoid arthristis ( juvenile) 4Reg. ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche TIRAGOLUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI TIRAGOLUMAB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII KADCYLA
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche TASPOGLUTIDE Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII TASPOGLUTIDE
Therapeutic area: Metabolic / Endocrinology
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII COTELLIC
Therapeutic area: Cancer
Roche SMN2 splicer (2) Biodrugs/ Drugs Musculoskeletal Disorders Spinal muscular atrophy and related syndromes 3PhIII SMN2 splicer (2)
Therapeutic area: Musculoskeletal Disorders
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII XELODA
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche CD20 CD3 TDB Biodrugs/ Drugs Blood and Lymphatic systems Non-hodgkin's lymphoma 1PhI CD20 CD3 TDB
Therapeutic area: Blood and Lymphatic systems
Roche SERD (2) Biodrugs/ Drugs Cancer Breast cancer 1PhI SERD (2)
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer other unspecificed types of non-hodgkin's lymphoma 2PhII Tecentriq
Therapeutic area: Cancer
Roche EM RA PRED DEV Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM RA PRED DEV
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII PICTILISIB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Pemphigus 3PhIII MABTHERA
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche HEMLIBRA Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII HEMLIBRA
Therapeutic area: Blood and Lymphatic systems
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation systemic sclerosis 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche TIRAGOLUMAB Biodrugs/ Drugs Cancer Solid tumor 2PhII TIRAGOLUMAB
Therapeutic area: Cancer
Roche MabThera Biodrugs/ Drugs Blood and Lymphatic systems Follicular ( nodular) non-hodgkin's lymphoma 3PhIII MabThera
Therapeutic area: Blood and Lymphatic systems
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche VALCYTE Biodrugs/ Drugs Autoimmune & Inflammation Transplanted organ and tissue status (Excl. complications) 3PhIII VALCYTE
Therapeutic area: Autoimmune & Inflammation
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer colorectal cancer 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche OX40 Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI OX40
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Metastases 2PhII COTELLIC
Therapeutic area: Cancer
Roche Tau Mab (37D3) Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII Tau Mab (37D3)
Therapeutic area: Central Nervous System
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ZELBORAF
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of prostate 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Peripheral Vascular Diseases 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche SERD(3) (9545) Biodrugs/ Drugs Cancer breast cancer metastatic 1PhI SERD(3) (9545)
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer Ovarian cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII APITOLISIB
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche SEMBRAGILINE Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII SEMBRAGILINE
Therapeutic area: Central Nervous System
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche herceptin Biodrugs/ Drugs Cancer Breast cancer 3PhIII herceptin
Therapeutic area: Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 3PhIII XELODA
Therapeutic area: Cancer
Roche EM ACTEMAB RA Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII EM ACTEMAB RA
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche VEFG- ANG2 Bsb Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 3PhIII VEFG- ANG2 Bsb
Therapeutic area: Ophthalmology and optometry
Roche Myostatin Biodrugs/ Drugs Musculoskeletal Disorders Duchenne muscular dystrophy 3PhIII Myostatin
Therapeutic area: Musculoskeletal Disorders
Roche ERIVEDGE Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Other disorders involving the immune mechanism 2PhII ERIVEDGE
Therapeutic area: Autoimmune & Inflammation / Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Metabolic / Endocrinology Thyrotoxicosis (hyperthyroidism) 3PhIII ACTEMRA
Therapeutic area: Metabolic / Endocrinology
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Pancreatic cancer 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche PLGF MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PLGF MAB
Therapeutic area: Cancer
Roche COTELLIC Biodrugs/ Drugs Cancer Plasma cell neoplasm 2PhII COTELLIC
Therapeutic area: Cancer
Roche Tecentriq Biodrugs/ Drugs Cancer breast cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche ALECTINIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECTINIB
Therapeutic area: Cancer
Roche FORTOVASE Biodrugs/ Drugs Infections HIV disease unspecified 2PhII FORTOVASE
Therapeutic area: Infections
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasms 3PhIII ZELBORAF
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 2PhII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche Asyn MAb Biodrugs/ Drugs Central Nervous System Parkinson's disease 2PhII Asyn MAb
Therapeutic area: Central Nervous System
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche XOLAIR Biodrugs/ Drugs Respiratory and Pulmonary system other diseases of upper respiratory tract 3PhIII XOLAIR
Therapeutic area: Respiratory and Pulmonary system
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Multiple Sclerosis 4Reg. OCREVUS
Therapeutic area: Central Nervous System
Roche BITOPERTIN Biodrugs/ Drugs Central Nervous System Schizophrenia 3PhIII BITOPERTIN
Therapeutic area: Central Nervous System
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII KADCYLA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of brain 3PhIII AVASTIN
Therapeutic area: Cancer
Roche CEACAM5 CEA TCB Biodrugs/ Drugs Cancer Solid tumor 1PhI CEACAM5 CEA TCB
Therapeutic area: Cancer
Roche Esbriet Biodrugs/ Drugs Respiratory and Pulmonary system Idiophatic pulmonary fibrosis 2PhII Esbriet
Therapeutic area: Respiratory and Pulmonary system
Roche Tecentriq Biodrugs/ Drugs Cancer Head and neck cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche HERCEPTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 2PhII HERCEPTIN
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and unspecified parts of biliary tract 3PhIII GAZYVA
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer breast cancer 4Reg. AVASTIN
Therapeutic area: Cancer
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI TASELISIB
Therapeutic area: Cancer
Roche ALECENSA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECENSA
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Primary progresive multiple sclerosis 3PhIII OCREVUS
Therapeutic area: Central Nervous System
Roche OCRELIZUMAB Biodrugs/ Drugs Central Nervous System Musculoskeletal Disorders 3PhIII OCRELIZUMAB
Therapeutic area: Central Nervous System
Roche LEBRIKIZUMAB Biodrugs/ Drugs Respiratory and Pulmonary system Other diseases of upper respiratory tract 2PhII LEBRIKIZUMAB
Therapeutic area: Respiratory and Pulmonary system
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII AVASTIN
Therapeutic area: Cancer
Roche Cergutuzumab amunaleukin Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI Cergutuzumab amunaleukin
Therapeutic area: Cancer
Roche FENEBRUTINIB Biodrugs/ Drugs Autoimmune & Inflammation systemic lupus erythematosus 2PhII FENEBRUTINIB
Therapeutic area: Autoimmune & Inflammation
Roche Tecentriq Biodrugs/ Drugs Cancer Hepatocellular carcinoma 3PhIII Tecentriq
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI APITOLISIB
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Central Nervous System Relapsing-remitting multiple sclerosis 3PhIII OCREVUS
Therapeutic area: Central Nervous System
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 2PhII LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche GPC3 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of liver 2PhII GPC3 MAB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII PERJETA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Cervical cancer 2PhII AVASTIN
Therapeutic area: Cancer
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI VANUCIZUMAB
Therapeutic area: Cancer
Roche ALECENSA Biodrugs/ Drugs Cancer Non-small cell lung cancer 4Reg. ALECENSA
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII ALEGLITAZAR
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche MERICITABINE Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII MERICITABINE
Therapeutic area: Infections
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII AVASTIN
Therapeutic area: Cancer
Roche DSTA4637S Biodrugs/ Drugs Infections Bacterial infection of unespecified site 1PhI DSTA4637S
Therapeutic area: Infections
Roche Idasanutlin Biodrugs/ Drugs Blood and Lymphatic systems Leukaemia Acute 3PhIII Idasanutlin
Therapeutic area: Blood and Lymphatic systems
Roche Tecentriq Biodrugs/ Drugs Cancer kidney cancer 3PhIII Tecentriq
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI APITOLISIB
Therapeutic area: Cancer
Roche OCREVUS Biodrugs/ Drugs Cancer Renal cancer carncinoma 3PhIII OCREVUS
Therapeutic area: Cancer
Roche NEORECORMON Biodrugs/ Drugs Blood and Lymphatic systems Anaemia in neoplastic disease 2PhII NEORECORMON
Therapeutic area: Blood and Lymphatic systems
Roche HPV16 TI Biodrugs/ Drugs Infections Viral agents as cause of diseases classified to other 2PhII HPV16 TI
Therapeutic area: Infections
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII PERJETA
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Colorectal cancer 2PhII AVASTIN
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 1PhI VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche Balovaptan Biodrugs/ Drugs Central Nervous System Autism 3PhIII Balovaptan
Therapeutic area: Central Nervous System